GlassScriptPhysician profile
Carl R Lang
NPI 1730167339
$9,609.91
in general payments reported to CMS, 2019-2025
39 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $644 · 2021: $2,532 · 2022: $976 · 2023: $1,348 · 2024: $1,608 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,510.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,298.17 | 2021 | |
| Abbvie INC. | $1,230.77 | 2021-2025 | |
| Pfizer INC. | $1,179.34 | 2019-2025 | |
| Amgen INC. | $957.46 | 2019-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $695.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $579.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $577.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $544.58 | 2019-2020 | |
| Esperion Therapeutics, INC. | $273.69 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $271.35 | 2019-2025 | Spravato, Xarelto |
| Amarin Pharma, INC. | $215.01 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.39 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $207.48 | 2024-2025 | Auvelity, Symbravo |
| Idorsia Pharmaceuticals US INC | $181.72 | 2022-2025 | Quviviq, Quviviq |
| E.R. Squibb & Sons, L.L.C. | $151.37 | 2019-2025 | Eliquis, Camzyos |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.